China Pharma, Biotech Firms Could Lift Guidance After Strong Earnings -- Market Talk

Dow Jones

02/24

1005 GMT - Chinese pharma and biotech firms are poised to deliver solid 2H results, driven by stronger-than-expected innovative drug sales and licensing income, Citi analysts say in a note. Fosun Pharma's revenue could beat forecasts due to its business development deal with Pfizer, while Hansoh Pharma's results are expected to meet expectations as innovative drug sales track guidance. Most contract development and manufacturing organizations have issued positive profit alerts, and further guidance upgrades are likely. Specifically, WuXi AppTec's launch of its orforglipron drug may lift its revenue and profit outlook. Citi has a positive catalyst watch on names that could deliver earnings beats and guidance raises, including United Imaging, Pharmaron and Yifeng. (jason.chau@wsj.com)

(END) Dow Jones Newswires

February 24, 2026 05:05 ET (10:05 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2613794736"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613794736\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613794736?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 18:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613794736","market":"nz","top_or_hot":-1,"title":"China Pharma, Biotech Firms Could Lift Guidance After Strong Earnings -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1005 GMT - Chinese pharma and biotech firms are poised to deliver solid 2H results, driven by stronger-than-expected innovative drug sales and licensing income, Citi analysts say in a note. Fosun Pharma's revenue could beat forecasts due to its business development deal with Pfizer, while Hansoh Pharma's results are expected to meet expectations as innovative drug sales track guidance. Most contract development and manufacturing organizations have issued positive profit alerts, and further guidance upgrades are likely. Specifically, WuXi AppTec's launch of its orforglipron drug may lift its revenue and profit outlook. Citi has a positive catalyst watch on names that could deliver earnings beats and guidance raises, including United Imaging, Pharmaron and Yifeng. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2026 05:05 ET (10:05 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Pharma, Biotech Firms Could Lift Guidance After Strong Earnings -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Pharma, Biotech Firms Could Lift Guidance After Strong Earnings -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-24 18:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1005 GMT - Chinese pharma and biotech firms are poised to deliver solid 2H results, driven by stronger-than-expected innovative drug sales and licensing income, Citi analysts say in a note. Fosun Pharma's revenue could beat forecasts due to its business development deal with Pfizer, while Hansoh Pharma's results are expected to meet expectations as innovative drug sales track guidance. Most contract development and manufacturing organizations have issued positive profit alerts, and further guidance upgrades are likely. Specifically, WuXi AppTec's launch of its orforglipron drug may lift its revenue and profit outlook. Citi has a positive catalyst watch on names that could deliver earnings beats and guidance raises, including United Imaging, Pharmaron and Yifeng. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2026 05:05 ET (10:05 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2613794736","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613794736","pubTimestamp":1771927500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1005 GMT - Chinese pharma and biotech firms are poised to deliver solid 2H results, driven by stronger-than-expected innovative drug sales and licensing income, Citi analysts say in a note. Fosun Pharma's revenue could beat forecasts due to its business development deal with Pfizer, while Hansoh Pharma's results are expected to meet expectations as innovative drug sales track guidance. Most contract development and manufacturing organizations have issued positive profit alerts, and further guidance upgrades are likely. Specifically, WuXi AppTec's launch of its orforglipron drug may lift its revenue and profit outlook. Citi has a positive catalyst watch on names that could deliver earnings beats and guidance raises, including United Imaging, Pharmaron and Yifeng. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","CPHI":"惠普森医药"},"translate_title":"中国制药和生物技术公司在强劲盈利后可能会上调指引——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"CPHI":1.5},"content_text":"1005 GMT - Chinese pharma and biotech firms are poised to deliver solid 2H results, driven by stronger-than-expected innovative drug sales and licensing income, Citi analysts say in a note. Fosun Pharma's revenue could beat forecasts due to its business development deal with Pfizer, while Hansoh Pharma's results are expected to meet expectations as innovative drug sales track guidance. Most contract development and manufacturing organizations have issued positive profit alerts, and further guidance upgrades are likely. Specifically, WuXi AppTec's launch of its orforglipron drug may lift its revenue and profit outlook. Citi has a positive catalyst watch on names that could deliver earnings beats and guidance raises, including United Imaging, Pharmaron and Yifeng. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2026 05:05 ET (10:05 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}